Schistosome vaccine adjuvants in preclinical and clinical research

Vaccines

Volumn 2, Issue 3, 2014, Pages 654-685

  Stephenson, Rachel ^a   You, Hong ^b   McManus, Donald ^b   Toth, Istvan ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Adjuvant; Helminth; Schistosoma; Vaccine

Indexed keywords

ADJUVANT; ALUMINUM POTASSIUM SULFATE; ANTIGEN; CHOLERA TOXIN; CPG MOTIF OLIGODEOXYNUCLEOTIDE; CYTOKINE; EMULSIFYING AGENT; FREUND ADJUVANT; GLUCOPYRANOSYL LIPID; IMIDAZOQUINOLINE DERIVATIVE; IMMUNOGLOBULIN G; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 4; LEWIS X POLYSACCHARIDE; LIPOSOME; MONTANIDE; NUCLEOTIDE; OLIGOSACCHARIDE; PAPAIN; PEPTIDE; PEPTIDOGLYCAN; POLYCYTIDYLIC ACID; POLYINOSINIC ACID; POLYSACCHARIDE; PROTEIN; SAPONIN; THYMIC STROMAL LYMPHOPROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE;

CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DRUG SCREENING; EMULSION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNIZATION; MYCOBACTERIUM BOVIS BCG; NONHUMAN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SCHISTOSOMA; SCHISTOSOMIASIS; SCIENTIST; SECRETION (PROCESS); WORLD HEALTH ORGANIZATION;

EID: 84907430938     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines2030654     Document Type: Review

References (115)

1. Harris, N.; Gause, W.C. To B or not to B: B cells and the Th2-type immune response to helminths. Trends Immunol. 2011, 32, 80–88.
2. Hotez, P.J.; Bethony, J.M.; Diemert, D.J.; Pearson, M.; Loukas, A. Developing vaccines to combat hookworm infection and intestinal schistosomiasis. Nat. Rev. Microbiol. 2010, 8, 814–826.
3. McManus, D.P.; Loukas, A. Current status of vaccines for schistosomiasis. Clin. Microbiol. Rev. 2008, 21, 225–242.
4. Pearce, E.J.; MacDonald, A.S. The immunobiology of schistosomiasis. Nat. Rev. Immunol. 2002, 2, 499–511.
5. Mo, A.X.; Agosti, J.M.; Walson, J.L.; Hall, B.F.; Gordon, L. Schistosomiasis elimination strategies and potential role of a vaccine in achieving global health goals. Am. J. Trop. Med. Hyg. 2014, 90, 54–60.
6. Mata, E.; Salvador, A.; Igartua, M.; Hernandez, R.M.; Pedraz, J.L. Malaria vaccine adjuvants: Latest update and challenges in preclinical and clinical research. Biomed. Res. Int. 2013, doi:10.1155/2013/282913.
7. Jenkins, S.J.; Hewitson, J.P.; Jenkins, G.R.; Mountford, A.P. Modulation of the host’s immune response by schistosome larvae. Parasite Immunol. 2005, 27, 385–393.
8. Lebens, M.; Sun, J.B.; Czerkinsky, C.; Holmgren, J. Current status and future prospects for a vaccine against schistosomiasis. Expert Rev. Vaccines 2004, 3, 315–328.
9. Atochina, O.; Da’dara, A.A.; Walker, M.; Harn, D.A. The immunomodulatory glycan LNFPIII initiates alternative activation of murine macrophages in vivo. Immunology 2008, 125, 111–121.
10. Liang, Y.J.; Luo, J.; Lu, Q.; Zhou, Y.; Wu, H.W.; Zheng, D.; Ren, Y.Y.; Sun, K.Y.; Wang, Y.; Zhang, Z.S. Gene profile of chemokines on hepatic stellate cells of schistosome-infected mice and antifibrotic roles of CXCL9/10 on liver non-parenchymal cells. PLoS One 2012, 7, e42490.
11. Capron, A.; Riveau, G.; Capron, M.; Trottein, F. Schistosomes: The road from host-parasite interactions to vaccines in clinical trials. Trends Parasitol. 2005, 21, 143–149.
12. Moyle, P.M.; Toth, I. Self-Adjuvanting lipopeptide vaccines. Curr. Med. Chem. 2008, 15, 506–516.
13. Skwarczynski, M.; Toth, I. Lipid-Core-Peptide system for self-adjuvanting synthetic vaccine delivery. Bioconjug. Protoc. Strateg. Methods Second Ed. 2011, 751, 297–308.
14. Vogel, F.R. Improving vaccine performance with adjuvants. Clin. Infect. Dis. 2000, 30, S266–S270.
15. Cox, J.C.; Coulter, A.R. Adjuvants—A classification and review of their modes of action. Vaccine 1997, 15, 248–256.
16. Gobert, G.N.; McManus, D.P. Update on paramyosin in parasitic worms. Parasitol. Int. 2005, 54, 101–107.
17. Powell, M.F.; Newman, M.J.; Burdman, J.R. Vaccine design: The subunit and adjuvant approach. Powell, M.F., Newman, M.J., Eds. Plenum Press: New York, NY, USA, 1995.
18. McWilliam, H.E.G.; Driguez, P.; Piedrafita, D.; McManus, D.P.; Meeusen, E.N.T. Novel immunomic technologies for schistosome vaccine development. Parasite Immunol. 2012, 34, 276–284.
19. Pacifico, L.G.G.; Fonseca, C.T.; Chiari, L.; Oliveira, S.C. Immunization with Schistosoma mansoni 22.6 kDa antigen induces partial protection against experimental infection in a recombinant protein form but not as DNA vaccine. Immunobiology 2006, 211, 97–104.
20. Dougall, A.M.; Skwarczynski, M.; Khoshejad, M.; Chandrudu, S.; Daly, N.L.; Toth, I.; Loukas, A. Lipid core peptide targeting the cathepsin D hemoglobinase of Schistosoma mansoni as a component of a schostosomiasis vaccine. Hum. Vaccines Immunother. 2014, 10, 1–11.
21. Wu, Z.D.; Lu, Z.Y.; Yu, X.B. Development of a vaccine against Schistosoma japonicum in China: A review. Acta Trop. 2005, 96, 106–116.
22. Boulanger, D.; Schneider, D.; Chippaux, J.P.; Sellin, B.; Capron, A. Schistosoma bovis: Vaccine effects of a recombinant homologous glutathione S-transferase in sheep. Int. J. Parasitol. 1999, 29, 415–418.
23. Xiong, Y.N.; Zhang, M.; Hong, Y.; Wei, M.M.; Ai, D.Z.; Meng, P.P.; Han, Y.H.; Fu, Z.Q.; Shi, Y.J.; Yang, J.M.; et al. Characterization analysis of Schistosoma japonicum plasma membrane repair relative gene myoferlin. PLoS One 2013, doi:10.1371/journal.pone.0066396.
24. McManus, D.P.; Bartley, P.B. A vaccine against Asian schistosomiasis. Parasitol. Int. 2004, 53, 163–173.
25. McManus, D.P. Prospects for development of a transmission blocking vaccine against Schistosoma japonicum. Parasite Immunol. 2005, 27, 297–308.
26. El Ridi, R.; Tallima, H. Adjuvant selection for vaccination against murine schistosomiasis. Scand. J. Immunol. 2012, 76, 552–558.
27. Feng, Z.Q.; Zhong, S.G.; Li, Y.H.; Li, Y.Q.; Qiu, Z.N.; Wang, Z.M.; Li, J.; Dong, L.; Guan, X.H. Nanoparticles as a vaccine adjuvant of anti-idiotypic antibody against schistosomiasis. Chin. Med. J. 2004, 117, 83–87.
28. Ohs, I.; Windmann, S.; Wildner, O.; Dittmer, U.; Bayer, W. Interleukin-Encoding adenoviral vectors as genetic adjuvant for vaccination against retroviral infection. PLoS One 2013, doi:10.1371/journal.pone.0082528.
29. Okano, M.; Satoskar, A.R.; Nishizaki, K.; Harn, D.A. Lacto-N-fucopentaose III found on Schitosoma mansoni egg antigens functions as adjuvant for proteins by inducing Th2-type response. J. Immunol. 2001, 167, 442–450
30. Balloul, J.M.; Grzych, J.M.; Pierce, R.J.; Capron, A. A purified 28,000 dalton protein from Schistosoma-mansoni adult worms protects rats and mice against experimental schistosomiasis. J. Immunol. 1987, 138, 3448–3453.
31. Boulanger, D.; Reid, G.D.F.; Sturrock, R.F.; Wolowczuk, I.; Balloul, J.M.; Grezel, D.; Pierce, R.J.; Otieno, M.F.; Guerret, S.; Grimaud, J.A.; et al. Immunization of mice and baboons with the recombinant Sm28GST affects both worm viability and fecundity after experimental-infection with schistosoma-mansoni. Parasite Immunol. 1991, 13, 473–490.
32. Geldhof, P.; de Maere, V.; Vercruysse, J.; Claerebout, E. Recombinant expression systems: The obstacle to helminth vaccines? Trends Parasitol. 2007, 23, 527–532.
33. Capron, A.; Capron, M.; Riveau, G. Vaccine development against schistosomiasis from concepts to clinical trials. Br. Med. Bull. 2002, 62, 139–148.
34. Chen, H.G.; Nara, T.; Zeng, X.J.; Satoh, M.; Wu, G.C.; Jiang, W.S.; Yi, F.Y.; Kojima, S.; Zhang, S.J.; Hirayama, K. Vaccination of domestic pig with recombinant paramyosin against Schistosoma japonicum in China. Vaccine 2000, 18, 2142–2146.
35. Ramos, C.R.R.; Vilar, M.M.; Nascimento, A.L.T.O.; Ho, P.L.; Thaumaturgo, N.; Edelenyi, R.; Almeida, M.; Dias, W.D.; Diogo, C.M.; Tendler, M. r-Sm14-pRSETA efficacy in experimental animals. Memorias Do Instituto Oswaldo Cruz 2001, 96, 131–135.
36. Vilar, M.M.; Barrientos, F.; Almeida, M.; Thaumaturgo, N.; Simpson, A.; Garratt, R.; Tendler, M. An experimental bivalent peptide vaccine against schistosomiasis and fascioliasis. Vaccine 2003, 22, 137–144.
37. Farias, L.P.; Rodrigues, D.; Cunna, V.; Rofatto, H.K.; Faquim-Mauro, E.L.; Leite, L.C.C. Schistosoma mansoni venom allergen like proteins present differential allergic responses in a murine model of airway inflammation. PLoS Negl. Trop. Dis. 2012, doi:10.1371/journal.pntd.0001510.
38. Tran, M.H.; Pearson, M.S.; Jeffrey, M.B.; Smyth, D.J.; Jones, M.K.; Duke, M.; Don, T.A.; McManus, D.P.; Correa-Oliveira, R.; Loukas, A. Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis. Nat. Med. 2006, 12, 835–840.
39. Araujo, J.M.; de Melo, T.T.; de Sena, I.C.; Alves, C.C.; Araujo, N.; Duraes, F.D.; Oliveira, S.C.; Fonseca, C.T. Schistosoma mansoni schistosomula tegument (Smteg) immunization in absence of adjuvant induce IL-10 production by CD4+ cells and failed to protect mice against challenge infection. Acta Trop. 2012, 124, 140–146.
40. Yan, Y.T.; Liu, S.X.; Song, G.C.; Xu, Y.X.; Dissous, C. Characterization of a novel vaccine candidate and serine proteinase inhibitor from Schistosoma japonicum (Sj serpin). Vet. Parasitol. 2005, 131, 53–60.
41. Liu, S.X.; Song, G.C.; Xu, Y.X.; Yang, W.; Mcmanus, D.P. Immunization of mice with recombinant Sjc26GST induces a pronounced anti-fecundity effect after experimental-infection with Chinese Schistosoma-japonicum. Vaccine 1995, 13, 603–607.
42. Abane, J.L.; Oleaga, A.; Ramajo, V.; Casanueva, P.; Arellano, J.L.P.; Hillyer, G.V.; Muro, A. Vaccination of mice against Schistosoma bovis with a recombinant fatty acid binding protein from Fasciola hepatica. Vet. Parasitol. 2000, 91, 33–42.
43. Kohama, H.; Harakuni, T.; Kikuchi, M.; Nara, T.; Takemura, Y.; Miyata, T.; Sato, Y.; Hirayama, K.; Arakawa, T. Intranasal administration of Schistosoma japonicum paramyosin induced robust long-lasting systemic and local antibody as well as delayed-type hypersensitivity responses, but failed to confer protection in a mouse infection model. Jpn. J. Infect. Dis. 2010, 63, 166–172.
44. Al-Sherbiny, M.; Osman, A.; Barakat, R.; el Morshedy, H.; Bergquist, R.; Olds, R. In vitro cellular and humoral responses to Schistosoma mansoni vaccine candidate antigens. Acta Trop. 2003, 88, 117–130.
45. Xu, X.D.; Zhang, D.M.; Sun, W.; Zhang, Q.F.; Zhang, J.J.; Xue, X.Y.; Shen, L.H.; Pan, W.Q. A Schistosoma japonicum chimeric protein with a novel adjuvant induced a polarized Th1 immune response and protection against liver egg burdens. BMC Infect. Dis. 2009, doi:10.1186/1471-2334-9-54.
46. Karmakar, S.; Zhang, W.; Ahmad, G.; Torben, W.; Alam, M.U.; Le, L.; Damian, R.T.; Wolf, R.F.; White, G.L.; Carey, D.W.; et al. Cross-species protection: Schistosoma mansoni Sm-p80 vaccine confers protection against Schistosoma haematobium in hamsters and baboons. Vaccine 2014, 32, 1296–1303.
47. Zhang, Y.; Taylor, M.G.; Johansen, M.V.; Bickle, Q.D. Vaccination of mice with a cocktail DNA vaccine induces a Th1-type immune response and partial protection against Schistosoma japonicum infection. Vaccine 2002, 20, 724–730.
48. Fan, J.J.; Gan, X.X.; Yang, W.; Shen, L.Y.; McManus, D.P.; Brindley, P.J. A Schistosoma japonicum very low-density lipoprotein-binding protein. Int. J. Biochem. Cell Biol. 2003, 35, 1436–1451.
49. Zhang, D.M.; Pan, W.Q.; Qian, L.; Duke, M.; Shen, L.H.; McManus, D.P. Investigation of recombinant Schistosoma japonicum paramyosin fragments for immunogenicity and vaccine efficacy in mice. Parasite Immunol. 2006, 28, 77–84.
50. Verity, C.K.; McManus, D.P.; Brindley, P.J. Vaccine efficacy of recombinant cathepsin D aspartic protease from Schistosoma japonicum. Parasite Immunol. 2001, 23, 153–162.
51. You, H.; Gobert, G.N.; Duke, M.G.; Zhang, W.B.; Li, Y.S.; Jones, M.K.; McManus, D.P. The insulin receptor is a transmission blocking veterinary vaccine target for zoonotic Schistosoma japonicum. Int. J. Parasitol. 2012, 42, 801–807.
52. Gameiro, S.R. Pulmonary delivery of liposome-based vaccines: Application to a murine model of schistosoma mansoni infection. Ph.D. Thesis, State University of New York, Buffalo, NY, 2008.
53. Ivanoff, N.; Phillips, N.; Schacht, A.M.; Heydari, C.; Capron, A.; Riveau, G. Mucosal vaccination against schistosomiasis using liposome-associated Sm 28 kDa glutathione S-transferase. Vaccine 1996, 14, 1123–1131.
54. Ahmad, G.; Zhang, W.D.; Torben, W.; Ahrorov, A.; Damian, R.T.; Wolf, R.F.; White, G.L.; Carey, D.W.; Mwinzi, P.N.M.; Ganley-Leal, L.; et al. Preclinical prophylactic efficacy testing of sm-p80-based vaccine in a nonhuman primate model of Schistosoma mansoni infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemic. J. Infect. Dis. 2011, 204, 1437–1449.
55. Torben, W.; Ahmad, G.; Zhang, W.D.; Siddiqui, A.A. Role of antibodies in Sm-p80-mediated protection against Schistosoma mansoni challenge infection in murine and nonhuman primate models. Vaccine 2011, 29, 2262–2271.
56. Ahmad, G.; Zhang, W.D.; Torben, W.; Noor, Z.; Siddiqui, A.A. Protective effects of Sm-p80 in the presence of resiquimod as an adjuvant against challenge infection with Schistosoma mansoni in mice. Int. J. Infect. Dis. 2010, 14, E781–E787.
57. Zhu, Y.C.; Ren, J.G.; Da’dara, A.; Harn, D.; Xu, M.; Si, J.; Yu, C.X.; Liang, Y.S.; Ye, P.; Yin, X.R.; et al. The protective effect of a Schistosoma japonicum chinese strain 23 kDa plasmid DNA vaccine in pigs is enhanced with IL-12. Vaccine 2004, 23, 78–83.
58. Cao, H.; Xiong, J.; Liu, J.; Feng, Q.; Gan, Y.; Youen, S. Studies on effect enhancement of vegetal polysaccharide on Schistosoma japonicum DNA vaccine pv1223. Chin. Pharm. J. 2006, 41, 899–901.
59. Wei, F.; Liu, Q.; Gao, S.Y.; Shang, L.M.; Zhai, Y.J.; Men, J.T.; Jiang, L.; Zhu, X.Q.; Fu, Z.Q.; Shi, Y.J.; et al. Enhancement by IL-18 of the protective effect of a Schistosoma japonicum 26 kDa GST plasmid DNA vaccine in mice. Vaccine 2008, 26, 4145–4149.
60. El Ridi, R.; Tallima, H. Vaccine-induced protection against murine Schistosomiasis mansoni with larval excretory-secretory antigens and papain or type-2 cytokines. J. Parasitol. 2013, 99, 194–202.
61. Pearce, E.J.; James, S.L.; Hieny, S.; Lanar, D.E.; Sher, A. Induction of protective immunity against Schistosoma-mansoni by vaccination with Schistosome paramyosin (Sm97), a nonsurface parasite antigen. Proc. Natl. Acad. Sci. USA 1988, 85, 5678–5682.
62. El Ridi, R.; Tallima, H.; Selim, S.; Donnelly, S.; Cotton, S.; Santana, B.G.; Dalton, J.P. Cysteine peptidases as schistosomiasis vaccines with inbuilt adjuvanticity. PLoS One 2014, doi:10.1371/journal.pone.0085401.
63. Hacariz, O.; Sayers, G.; McCullough, M.; Garrett, M.; O’Donovan, J.; Mulcahy, G. The effect of quil a adjuvant on the course of experimental Fasciola hepatica infection in sheep. Vaccine 2009, 27, 45–50.
64. Deeb, B.J.; Digiacomo, R.F.; Kunz, L.L.; Stewart, J.L. Comparison of Freund and Ribi adjuvants for inducing antibodies to the synthetic antigen (TG)-AL in rabbits. J. Immunol. Methods 1992, 152, 105–113.
65. Sabin Vaccine Institute. Schistosimiasis Vaccine: Project Status. Available online: http://www.Sabin.Org/programs/schistosomiasis-vaccine/project-status (accessed on 9 April 2014).
66. Clegg, C.H.; Roque, R.; van Hoeven, N.; Perrone, L.; Baldwin, S.L.; Rininger, J.A.; Bowen, R.A.; Reed, S.G. Adjuvant solution for pandemic influenza vaccine production. Proc. Natl. Acad. Sci. USA 2012, 109, 17585–17590.
67. Coler, R.N.; Baldwin, S.L.; Shaverdian, N.; Bertholet, S.; Reed, S.J.; Raman, V.S.; Lu, X.H.; DeVos, J.; Hancock, K.; Katz, J.M.; et al. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One 2010, doi:10.1371/journal.pone.0013677.
68. Petrovsky, N.; Aguilar, J.C. Vaccine adjuvants: Current state and future trends. Immunol. Cell Biol. 2004, 82, 488–496.
69. Maghraby, A.S.; Shaker, K.H.; Gaber, H.M. Cross-Reactivity of Schistosoma mansoni-Fasciola gigantica influenced by saponins. Z. Fur. Naturforsch. C J. Biosci. 2009, 64, 288–296.
70. Mastelic, B.; Ahmed, S.; Egan, W.M.; del Giudice, G.; Golding, H.; Gust, I.; Neels, P.; Reed, S.G.; Sheets, R.L.; Siegrist, C.A.; et al. Mode of action of adjuvants: Implications for vaccine safety and design. Biologicals 2010, 38, 594–601.
71. Laman, A.G.; Shepelyakovskaya, A.O.; Berezin, I.A.; Boziev, K.M.; Rodionov, I.L.; Chulina, I.A.; Malakhova, V.; Brovko, F.A.; Murashev, A.N.; Korpela, T.K.; et al. Identitication of pentadecapeptide mimicking muramyl peptide. Vaccine 2007, 25, 2900–2906.
72. Byram, J.E.; Sher, A.; Dipietro, J.; Lichtenberg, F.V. Potentiation of Schistosome granuloma formation—By lentinan—T-cell adjuvant. Am. J. Pathol. 1979, 94, 201–222.
73. Velupillai, P.; dos Reis, E.A.; dos Reis, M.G.; Harn, D.A. Lewis(x)-containing oligosaccharide attenuates schistosome egg antigen-induced immune depression in human schistosomiasis. Hum. Immunol. 2000, 61, 225–232.
74. Fortier, M.E.; Kent, S.; Ashdown, H.; Poole, S.; Boksa, P.; Luheshi, G.N. The viral mimic, polyinosinic: Polycytidylic acid, induces fever in rats via an interleukin-1-dependent mechanism. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004, 287, R759–R766.
75. Hou, X.; Yu, F.Z.; Man, S.Q.; Huang, D.; Zhang, Y.X.; Liu, M.; Ren, C.P.; Shen, J.J. Polyinosinic-Polycytidylic acid attenuates hepatic fibrosis in C57BL/6 mice with Schistosoma japonicum infection. Acta Trop. 2012, 121, 99–104.
76. Weiner, G.J.; Liu, H.M.; Wooldridge, J.E.; Dahle, C.E.; Krieg, A.M. Immunostimulatory oligodeoxynucleotides containing the cpg motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. USA 1997, 94, 10833–10837.
77. Coley, W.B. The classic: The treatment of malignant-tumors by repeated inoculations of erysipelas-with a report of 10 original cases. Clin. Orthop. Relat. Res. 1991, 262, 3–11.
78. Krieg, A.M.; Yi, A.K.; Matson, S.; Waldschmidt, T.J.; Bishop, G.A.; Teasdale, R.; Koretzky, G.A.; Klinman, D.M. CpG motifs in bacterial-DNA trigger direct B-cell activation. Nature 1995, 374, 546–549.
79. Pearce, E.J. Progress towards a vaccine for schistosomiasis. Acta Trop. 2003, 86, 309–313.
80. Lu, J.; Jiang, S.; Ye, S.; Deng, Y.; Ma, S.; Li, C.-P. CpG oligodeoxynucleotide ligand potentiates the activity of the pVAX1-Sj26gst. Biomed. Res. 2013, 4, 609–613.
81. Wang, X.F.; Dong, L.Y.; Ni, H.C.; Zhou, S.; Xu, Z.P.; Hoellwarth, J.S.; Chen, X.J.; Zhang, R.B.; Chen, Q.Y.; Liu, F.; et al. Combined TLR7/8 and TLR9 ligands potentiate the activity of a Schistosoma japonicum DNA vaccine. PLoS Negl. Trop. Dis. 2013, doi:10.1371/journal.pntd.0002164.
82. Kasturi, S.P.; Skountzou, I.; Albrecht, R.A.; Koutsonanos, D.; Hua, T.; Nakaya, H.I.; Ravindran, R.; Stewart, S.; Alam, M.; Kwissa, M.; et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011, 470, 543–547.
83. Buchan, S.; Gronevik, E.; Mathiesen, I.; King, C.A.; Stevenson, F.K.; Rice, J. Electroporation as a ―prime/boost‖ strategy for naked DNA vaccination against a tumor antigen. J. Immunol. 2005, 174, 6292–6298.
84. Ahmad, G.; Zhang, W.D.; Torben, W.; Haskins, C.; Diggs, S.; Noor, Z.; Le, L.; Siddiqui, A.A. Prime-Boost and recombinant protein vaccination strategies using Sm-p80 protects against Schistosoma mansoni infection in the mouse model to levels previously attainable only by the irradiated cercarial vaccine. Parasitol. Res. 2009, 105, 1767–1777.
85. DA’Dara, A.A.; Skelly, P.J.; Walker, C.M.; Harn, D.A. A DNA-prime/protein-boost vaccination regimen enhances Th2 immune responses but not protection following Schistosoma mansoni infection. Parasite Immunol. 2003, 25, 429–437.
86. Dai, Y.; Zhu, Y.C.; Harn, D.A.; Wang, X.T.; Tang, J.X.; Zhao, S.; Lu, F.; Guan, X.H. DNA vaccination by electroporation and boosting with recombinant proteins enhances the efficacy of DNA vaccines for Schistosomiasis japonica. Clin. Vaccine Immunol. 2009, 16, 1796–1803.
87. Shalaby, K.A.; Yin, L.; Thakur, A.; Christen, L.; Niles, E.G.; LoVerde, P.T. Protection against Schistosoma mansoni utilizing DNA vaccination with genes encoding Cu/Zn cytosolic superoxide dismutase, signal peptide-containing superoxide dismutase and glutathione peroxidase enzymes. Vaccine 2003, 22, 130–136.
88. Siddiqui, A.A.; Siddiqui, B.A.; Ganley-Leal, L. Schistosomiasis vaccines. Hum. Vaccines 2011, 7, 1192–1197.
89. Nohria, A.; Rubin, R.H. Cytokines as potential vaccine adjuvants. Biotherapy 1994, 7, 261–269.
90. Peterson, A.C.; Harlin, H.; Gajewski, T.F. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J. Clin. Oncol. 2003, 21, 2342–2348.
91. Mountford, A.P.; Anderson, S.; Wilson, R.A. Induction of Th1 cell-mediated protective immunity to Schistosoma mansoni by co-administration of larval antigens and IL-12 as an adjuvant. J. Immunol. 1996, 156, 4739–4745.
92. Wynn, T.A.; Jankovic, D.; Hieny, S.; Cheever, A.W.; Sher, A. IL-12 enhances vaccine-induced immunity to Schistosoma-mansoni in mice and decreases T-helper-2 cytokine expression, IgE production, and tissue eosinophilia. J. Immunol. 1995, 154, 4701–4709.
93. Siddiqui, A.A.; Ahmad, G.; Damian, R.T.; Kennedy, R.C. Experimental vaccines in animal models for schistosomiasis. Parasitol. Res. 2008, 102, 825–833.
94. Da’Dara, A.A.; Li, Y.S.; Xiong, T.; Zhou, J.; Williams, G.M.; McManus, D.R.; Feng, Z.; Yu, X.L.; Gray, D.J.; Harn, D.A. DNA-Based vaccines protect against zoonotic schistosomiasis in water buffalo. Vaccine 2008, 26, 3617–3625.
95. Zhu, Y.; Si, J.; Harn, D.A.; Xu, M.; Ren, J.; Yu, C.; Liang, Y.; Yin, X.; He, W.; Cao, G. Schistosoma japonicum triose-phosphate isomerase plasmid DNA vaccine protects pigs against challenge infection. Parasitology 2006, 132, 67–71.
96. Fonseca, C.T.; Brito, C.F.A.; Alves, J.B.; Oliveira, S.C. IL-12 enhances protective immunity in mice engendered by immunization with recombinant 14 kDa Schistosoma mansoni fatty acid-binding protein through an IFN-gamma and TNF-alpha dependent pathway. Vaccine 2004, 22, 503–510.
97. Gilmour, J.; Lavender, P. Control of IL-4 expression in T helper 1 and 2 cells. Immunology 2008, 124, 437–444.
98. Samia, E.E.; Magda, A.E.; Sadek, G.S. Potential role of interleukin 4 and 12 as adjuvants to tegumental antigen in a vaccination model for murine Schistosomiasis mansoni. Parasitol. United J. 2013, 6, 65–76.
99. Eberl, M.; Beck, E.; Coulson, P.S.; Okamura, H.; Wilson, R.A.; Mountford, A.P. IL-18 potentiates the adjuvant properties of IL-12 in the induction of a strong Th1 type immune response against a recombinant antigen. Vaccine 2000, 18, 2002–2008.
100. Taylor, C.E. Cytokines as adjuvants for vaccines-antigen-specific responses differ from polyclonal responses. Infect. Immun. 1995, 63, 3241–3244.
101. Ziegler, S.F.; Artis, D. Sensing the outside world: TSLP regulates barrier immunity. Nat. Immunol. 2010, 11, 289–293.
102. Soumelis, V. Tslp: From allergy to vaccine adjuvant. Eur. J. Immunol. 2012, 42, 293–295.
103. James, S.L. Induction of protective immunity against Schistosoma-mansoni by a nonliving vaccine is dependent on the method of antigen presentation. J. Immunol. 1985, 134, 1956–1960.
104. James, S.L.; Pearce, E.J.; Sher, A. Induction of protective immunity against Schistosoma-mansoni by a non living vaccine. 1. Partial characterization of antigens recognized by antibodies from mice immunized with soluble schistosome extracts. J. Immunol. 1985, 134, 3432–3438.
105. Sher, A.; Pearce, E.; Hieny, S.; James, S. Induction of protective immunity against Schistosoma-mansoni by a nonliving vaccine. 4. Fractionation and antigenic properties of a soluble adult worm immunoprophylactic activity. J. Immunol. 1986, 136, 3878–3883.
106. James, S.L.; Pearce, E.J. The influence of adjuvant on induction of protective immunity by a non-living vaccine against schistosomiasis. J. Immunol. 1988, 140, 2753–2759.
107. Tsuji, N.; Suzuki, K.; Kasuga-Aoki, H.; Matsumoto, Y.; Arakawa, T.; Ishiwata, K.; Isobe, T. Intranasal immunization with recombinant ascaris suum 14-kilodalton antigen coupled with cholera toxin B subunit induces protective immunity to A-suum infection in mice. Infect. Immun. 2001, 69, 7285–7292.
108. ElRidi, R.; Tallima, H.P.; Dalton, J.; Donnelly, S. Induction of protective immune responses against schistosomiasis using functionally active cysteine peptidases. Front. Genet. 2014, doi:10.3389/fgene.2014.00119.
109. Chapman, M.D.; Wunschmann, S.; Pomes, A. Proteases as Th2 adjuvants. Curr. Allergy Asthma Rep. 2007, 7, 363–367.
110. Farah, I.O.; Kariuki, T.M.; King, C.L.; Hau, J. An overview of animal models in experimental schistosomiasis and refinements in the use of non-human primates. Lab. Anim-Uk 2001, 35, 205–212.
111. Cheever, A.W.; Lenzi, J.A.; Lenzi, H.L.; Andrade, Z.A. Experimental models of schistosoma mansoni infection. Mem. Inst. Oswaldo Cruz 2002, 97, 917–940.
112. Nyindo, M.; Farah, I.O. The baboon as a non-human primate model of human schistosome infection. Parasitol. Today 1999, 15, 478–482
113. Standley, C.J.; Mugisha, L.; Dobson, A.P.; Stothard, J.R. Zoonotic schistosomiasis in non-human primates: Past, present and future activities at the human-wildlife interface in Africa. J. Helminthol. 2012, 86, 131–140.
114. Ismail, O.A. Schistosomiasis vaccines: Literature review and current status. J. Egyp. Parasitol. United 2011, 4, 137–154.
115. Mutwiri, G.; Gerdts, V.; Little van den Hurk, S.V.. Auray, G.; Eng, N.; Garlapati, S.; Babiuk, L.A.; Potter, A. Combination adjuvants: The next generation of adjuvants? Expert Rev. Vaccines 2011, 10, 95–107.